MOR.DE
Price:
$67.25
Market Cap:
$2.53B
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a ...[Read more]
Industry
Biotechnology
IPO Date
1999-03-10
Stock Exchange
XETRA
Ticker
MOR.DE
According to MorphoSys AG’s latest financial reports and current stock price. The company's current Enterprise Value is 2.66B. This represents a change of 65.90% compared to the average of 1.60B of the last 4 quarters.
The mean historical Enterprise Value of MorphoSys AG over the last ten years is 2.01B. The current 2.66B Enterprise Value has changed 13.12% with respect to the historical average. Over the past ten years (40 quarters), MOR.DE's Enterprise Value was at its highest in in the December 2019 quarter at 4.01B. The Enterprise Value was at its lowest in in the December 2022 quarter at 388.44M.
Average
2.01B
Median
1.80B
Minimum
388.30M
Maximum
4.01B
Discovering the peaks and valleys of MorphoSys AG Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 323.40%
Maximum Annual Enterprise Value = 4.01B
Minimum Annual Increase = -70.50%
Minimum Annual Enterprise Value = 388.30M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.64B | 323.40% |
2022 | 388.30M | -70.50% |
2021 | 1.32B | -59.62% |
2020 | 3.26B | -18.63% |
2019 | 4.01B | 43.56% |
2018 | 2.79B | 28.86% |
2017 | 2.17B | 78.38% |
2016 | 1.21B | -13.81% |
2015 | 1.41B | -27.85% |
2014 | 1.95B | 50.65% |
The current Enterprise Value of MorphoSys AG (MOR.DE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.12B
5-year avg
2.12B
10-year avg
2.01B
MorphoSys AG’s Enterprise Value is greater than Evotec SE (1.76B), less than Qiagen N.V. (10.55B), less than United Internet AG (6.09B), less than Bechtle AG (4.37B), greater than Jenoptik AG (1.67B),
Company | Enterprise Value | Market cap |
---|---|---|
1.76B | $1.51B | |
10.55B | $8.86B | |
6.09B | $3.30B | |
4.37B | $4.02B | |
1.67B | $1.24B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MorphoSys AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MorphoSys AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is MorphoSys AG's Enterprise Value?
What is the highest Enterprise Value for MorphoSys AG (MOR.DE)?
What is the 3-year average Enterprise Value for MorphoSys AG (MOR.DE)?
What is the 5-year average Enterprise Value for MorphoSys AG (MOR.DE)?
How does the current Enterprise Value for MorphoSys AG (MOR.DE) compare to its historical average?